Luminity: Uses, Dosage & Side Effects

What Is Luminity and What Is It Used For?

Luminity (perflutren lipid microsphere injectable suspension) belongs to the pharmacological class of ultrasound contrast media. It was developed by Lantheus Medical Imaging and received its European marketing authorization from the European Medicines Agency (EMA) in 2006. In the United States and Canada, the same product is marketed under the brand name Definity. Both formulations are identical in composition, mechanism of action, and clinical application.

The primary indication for Luminity is the enhancement of echocardiographic endocardial border delineation in patients with suboptimal echocardiograms. In clinical practice, a significant proportion of echocardiographic studies — estimated at 10 to 20 percent of all transthoracic echocardiograms — produce images of insufficient quality for accurate interpretation. This can occur due to patient body habitus, lung disease, chest wall deformities, or post-surgical anatomy. When standard echocardiography fails to provide adequate visualization, Luminity offers a solution by dramatically enhancing the contrast between the blood pool within the left ventricle and the surrounding myocardial tissue.

The microspheres in Luminity consist of a perflutren (octafluoropropane) gas core enclosed within a phospholipid shell. These microspheres have a mean diameter of 1.1 to 3.3 micrometers, which is small enough to traverse the pulmonary capillary bed after intravenous injection. When these gas-filled microspheres encounter ultrasound energy, they oscillate and produce strong backscatter signals that create enhanced contrast in the ultrasound image. This effect allows the cardiologist to clearly visualize the endocardial border, enabling accurate measurement of left ventricular volumes, ejection fraction, and assessment of regional wall motion.

Beyond its primary indication in echocardiography, contrast-enhanced ultrasound with agents like Luminity has been explored in other diagnostic imaging contexts, including the assessment of myocardial perfusion and evaluation of liver lesions. However, these applications are considered off-label and are not included in the approved product labeling in all jurisdictions. The American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI) have both published guidelines supporting the use of ultrasound contrast agents to improve diagnostic accuracy in echocardiography when image quality is suboptimal.

Luminity is exclusively administered by healthcare professionals in a clinical setting equipped with resuscitation equipment. It is not a self-administered medication and requires specialized preparation using a mechanical activation device. The clinical benefit of Luminity has been demonstrated in multiple randomized controlled trials showing significant improvement in endocardial border delineation, inter-reader agreement among echocardiographers, and diagnostic confidence compared to unenhanced echocardiography.

What Should You Know Before Receiving Luminity?

Contraindications

Luminity must not be used in patients with certain medical conditions that significantly increase the risk of serious adverse events. The absolute contraindications for Luminity administration include known hypersensitivity to perflutren or to any of the inactive ingredients in the formulation, including the phospholipid components. Patients who have experienced a previous allergic reaction to Luminity, Definity, or any other perflutren-containing product should not receive it again.

A critical contraindication is the presence of known right-to-left, bi-directional, or transient right-to-left cardiac shunts. In these patients, the microspheres could bypass the pulmonary filtration system and enter the arterial circulation directly, potentially causing embolic events including stroke. This contraindication applies to conditions such as unrepaired atrial septal defects, ventricular septal defects, and patent foramen ovale with known right-to-left shunting. Healthcare providers must carefully evaluate patients for the presence of intracardiac shunts before administering Luminity.

Warnings and Precautions

The most significant safety concern with Luminity is the risk of serious cardiopulmonary reactions. Post-marketing surveillance has identified rare cases of cardiac arrest, respiratory arrest, loss of consciousness, convulsions, symptomatic arrhythmias, and anaphylactic shock occurring during or shortly after administration. While these events are exceedingly rare, their severity necessitates that Luminity be administered only in facilities equipped with resuscitation equipment and staffed by personnel trained in cardiopulmonary resuscitation.

Luminity should be used with particular caution in patients with the following conditions: severe pulmonary hypertension (pulmonary artery pressure greater than 90 mmHg), unstable cardiopulmonary conditions, acute myocardial infarction or acute coronary syndromes, serious ventricular arrhythmias or high-risk for arrhythmias, respiratory distress syndrome, severe emphysema, and pulmonary emboli or other conditions causing significant pulmonary vascular restriction. In these patients, the potential benefit of enhanced imaging must be carefully weighed against the potential risks.

The phospholipid shell of Luminity microspheres contains polyethylene glycol (PEG) as a component of the MPEG5000-DPPE excipient. Patients with known or suspected allergy to PEG should not receive Luminity. PEG allergy has become increasingly recognized, and healthcare providers should specifically ask about PEG sensitivity before administration. High mechanical index ultrasound settings can cause destruction of the microspheres and should be avoided during the imaging procedure, as this may reduce image quality and theoretically cause local bioeffects.

Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of Luminity in pregnant women. Animal reproduction studies have not demonstrated clear evidence of teratogenicity or harm to the fetus, but these studies are not always predictive of human response. Luminity should be used during pregnancy only if the expected diagnostic benefit clearly justifies the potential risk to the fetus. In most clinical scenarios, the echocardiographic study can be deferred until after delivery, or alternative imaging modalities such as cardiac MRI can be considered.

It is not known whether perflutren or the lipid shell components of Luminity are excreted in human breast milk. However, given the extremely short half-life of perflutren (approximately 1.3 minutes for pulmonary elimination), the systemic exposure is very brief. The lipid components are present in trace quantities. Most expert guidelines suggest that a brief interruption of breastfeeding (2 to 4 hours after administration) is a reasonable precaution, though the actual risk to the nursing infant is considered minimal. Women who are breastfeeding should discuss the timing of the procedure with their healthcare provider.

No data are available regarding the effects of Luminity on human fertility. Given the diagnostic nature of the product, its extremely short duration of action, and the absence of any pharmacological activity beyond ultrasound contrast enhancement, effects on fertility are not expected.

How Does Luminity Interact with Other Drugs?

One of the notable advantages of Luminity from a clinical safety perspective is its very favorable drug interaction profile. Perflutren is a chemically inert gas (octafluoropropane) that does not undergo hepatic metabolism and does not interact with cytochrome P450 (CYP) enzymes or other drug-metabolizing systems. The lipid shell components are present in extremely small quantities and are metabolized through endogenous lipid pathways. As a result, Luminity does not affect the pharmacokinetics or pharmacodynamics of co-administered medications.

No formal drug-drug interaction studies have been conducted with Luminity, primarily because the pharmacological properties of the product make clinically significant interactions extremely unlikely. The product is administered as a single diagnostic dose, has an extremely short duration of action (minutes), and does not accumulate in the body. These characteristics fundamentally differ from therapeutic drugs that are administered repeatedly and maintain sustained plasma concentrations.

Considerations for Concurrent Medications

Although no drug-drug interactions are expected, there are practical considerations when Luminity is administered to patients receiving other intravenous medications. Luminity should not be co-administered through the same intravenous line with other drugs unless compatibility has been established. The lipid microspheres may be destabilized by certain intravenous solutions or medications, potentially reducing the contrast enhancement effect. A dedicated intravenous line or thorough flushing with 0.9% sodium chloride between administrations is recommended.

Patients undergoing echocardiography with Luminity may be receiving various cardiovascular medications including beta-blockers, calcium channel blockers, ACE inhibitors, anticoagulants, and antiplatelet agents. None of these medications are known to interact with Luminity or to affect its diagnostic performance. Similarly, patients may continue their regular medication regimen without any dosage adjustments before or after the contrast echocardiographic study.

Ultrasound Equipment Settings

While not a drug interaction in the traditional sense, the ultrasound equipment settings used during the imaging procedure can significantly affect the performance of Luminity. High mechanical index (MI) ultrasound can cause premature destruction of the microspheres, reducing the duration and quality of contrast enhancement. Cardiologists should use low mechanical index settings during contrast-enhanced imaging to preserve the microspheres and optimize image quality. Most modern echocardiographic systems have dedicated contrast imaging protocols that automatically adjust the MI to appropriate levels.

What Is the Correct Dosage of Luminity?

Luminity must be activated before use by mechanical agitation using the Vialmix device, which is a specialized shaking apparatus provided by the manufacturer. The activation process generates the perflutren lipid microspheres from the clear to translucent lipid solution. After activation, the product appears as a milky white suspension. The activated product should be used promptly, as the microspheres gradually lose their gas content over time.

Bolus Administration (Adults)

Infusion Administration (Adults)

Pediatric Use

The safety and efficacy of Luminity have not been established in pediatric patients (under 18 years of age). The use of Luminity in children is therefore not recommended unless the potential benefit outweighs the potential risk, and the decision is made by a specialist experienced in pediatric cardiac imaging. Some centers have used contrast-enhanced echocardiography in children under institutional protocols, but this remains an off-label application. Ongoing clinical studies are evaluating the safety and optimal dosing of perflutren-based contrast agents in pediatric populations.

Elderly Patients

No dosage adjustment is required for elderly patients. Clinical trials of Luminity included patients aged 65 years and older, and no overall differences in safety or efficacy were observed between elderly and younger adult patients. However, elderly patients may be more likely to have underlying cardiopulmonary conditions that require additional caution, and the 30-minute post-administration monitoring period should be strictly observed.

Preparation and Administration

Missed Dose

The concept of a missed dose does not apply to Luminity in the traditional sense, as it is a single-use diagnostic agent administered during an echocardiographic procedure. If the echocardiographic study is not completed or needs to be rescheduled, Luminity will simply be administered at the time of the rescheduled study. There are no consequences of delaying or rescheduling a contrast echocardiographic examination.

Overdose

Clinical experience with overdose of Luminity is limited. In clinical trials, doses up to 100 microliters/kg (10 times the recommended bolus dose) have been administered without serious adverse effects in healthy volunteers. In the event of overdose, treatment should be supportive and symptomatic. Given the extremely short half-life of perflutren and the rapid elimination through the lungs, the effects of an overdose would be expected to resolve quickly. Patients should be monitored for cardiopulmonary symptoms and treated with standard supportive measures as clinically indicated.

What Are the Side Effects of Luminity?

Luminity has been evaluated for safety in clinical trials involving thousands of patients undergoing contrast-enhanced echocardiography. The overall safety profile is favorable, with most adverse reactions being mild to moderate in severity and transient in duration. The majority of side effects resolve without intervention within minutes to hours after administration. However, rare but serious adverse events have been reported in post-marketing surveillance, necessitating appropriate monitoring and preparedness.

The following side effects are organized by frequency according to the Medical Dictionary for Regulatory Activities (MedDRA) system organ classification and the standard frequency convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), and rare (≥1/10,000 to <1/1,000).

It is important to note that the clinical setting in which Luminity is administered — typically a cardiac imaging laboratory — is staffed by healthcare professionals who are trained to recognize and manage adverse reactions. The 30-minute monitoring period following administration is specifically designed to identify and treat any serious reactions promptly. The vast majority of patients tolerate Luminity without significant adverse effects.

Post-marketing surveillance has provided additional safety data beyond what was observed in clinical trials. Rare cases of fatal cardiac arrests have been reported, primarily in patients with pre-existing serious cardiovascular disease. The causal relationship between Luminity administration and these fatal events has been difficult to establish definitively, as the patients were already critically ill. Nevertheless, the potential risk has led to the implementation of strict monitoring protocols and contraindications for high-risk patients.

Patients who have experienced a previous adverse reaction to Luminity or other perflutren-containing products should inform their healthcare provider, as they may be at increased risk of experiencing a reaction upon re-exposure. In such cases, the healthcare team will carefully weigh the diagnostic benefit against the potential risk and may consider alternative imaging approaches.

How Should You Store Luminity?

Proper storage of Luminity is essential to ensure the quality and efficacy of the product. The unactivated vials should be stored under refrigeration at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). Under these conditions, the product remains stable until the expiration date printed on the vial and outer packaging. Luminity must not be frozen, as freezing can damage the lipid formulation and compromise the quality of the microspheres formed upon activation.

Luminity may also be stored at controlled room temperature, up to 25 degrees Celsius (77 degrees Fahrenheit), for a defined period as specified in the product labeling (typically up to 24 to 48 hours, depending on the specific regulatory market). This flexibility allows for practical handling in imaging departments where refrigeration may not be immediately adjacent to the procedure room. However, vials that have been stored at room temperature should not be returned to refrigerated storage.

After activation using the Vialmix device, Luminity should be used as soon as possible. The activated microspheres begin to lose their gas content over time, which reduces the contrast enhancement effect. If the product is not used immediately after activation, it may be re-activated by repeating the mechanical agitation process. However, the total time between initial activation and administration should be minimized to ensure optimal imaging quality. The vial should be gently inverted before withdrawing each dose to ensure a uniform suspension of microspheres.

Luminity should be kept in the original packaging to protect from light. The product should not be used after the expiration date stated on the label. Any unused product or waste material should be disposed of in accordance with local institutional protocols for pharmaceutical waste. As a healthcare-administered product, patients will not typically need to store Luminity at home, as it is prepared and administered entirely within the clinical setting.

What Does Luminity Contain?

Active Ingredient

The active substance in Luminity is perflutren (octafluoropropane, C₃F₈), an inert perfluorocarbon gas. After activation, each milliliter of the suspension contains approximately 6.52 mg of octafluoropropane encapsulated within lipid microspheres. The microspheres have a mean diameter of 1.1 to 3.3 micrometers, and each milliliter contains a maximum of 1.2 × 10¹⁰ microspheres. Perflutren is pharmacologically inert and is eliminated unchanged through the lungs by exhalation.

Inactive Ingredients (Excipients)

The lipid shell of the microspheres is composed of three phospholipid components that provide structural integrity and biocompatibility:

• DPPA (1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, monosodium salt) — 0.045 mg/mL
• DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) — 0.401 mg/mL
• MPEG5000-DPPE (N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, monosodium salt) — 0.304 mg/mL

Additional excipients in the liquid phase include:

• Propylene glycol — a common pharmaceutical solvent
• Glycerin — acts as a stabilizer and tonicity agent
• Sodium chloride — for isotonicity
• Water for injection — the primary solvent

The headspace gas within the sealed vial (above the liquid) contains octafluoropropane and nitrogen. During the activation process, the mechanical agitation causes the headspace gas to be dispersed into the lipid solution, forming the microspheres that provide the ultrasound contrast effect. The MPEG5000-DPPE component contains polyethylene glycol (PEG), which is relevant for patients with known PEG allergy.

Luminity does not contain any preservatives, antimicrobial agents, latex, or natural rubber components. It is a single-use product, and any remaining contents should be discarded after the imaging procedure. The product is free from common allergens such as gluten, dairy, and egg proteins. However, as noted, patients with PEG hypersensitivity should not receive Luminity due to the PEG component in the phospholipid shell.